Clinical studies at the Bonn / Cologne site

7T-TGA (high-resolution MRI imaging in TGA patients: a retrospective and prospective study)

High-resolution MRI imaging as evidence of a structural cause in transient global amnesia (TGA), in which there is disruption of anterograde and also retrograde memory such that newly learned or experienced material is not retained.

ABCD (Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS))

The aim of this study is to investigate the influence of rituximab (Rixathon®) on the progression of disease in patients with amyotrophic lateral sclerosis (ALS) compared to a placebo. The study is funded by the German Federal Ministry of Education and Research (BMBF).

Alpha-FIT (Studie zur Verlangsamung des kognitiven Abbaus durch Steigerung der körperlichen Aktivität)

Does a smartphone-based exercise intervention have positive effects on cognitive performance in individuals with isolated REM sleep behavior disorder?

ARCA (Autosomal-Recessive Cerebellar Ataxias)

In this DZNE network research project (Autosomal Recessive Cerebellar Ataxia Registry, ARCA registry), modern methods are being used to search for new ataxia genes and biomarkers in autosomal recessive ataxias and early onset ataxias with onset before the age of 40.

AVERT-MD (Avatar Evaluation in Real-Time for Movement Disorders)

Development of digital biomarkers for the early diagnosis of movement disorders and monitoring of disease progression using technologies from the fields of virtual reality (VR), mobile applications and sensor-/video-based motion capture systems (MoCap), as well as the creation of photorealistic 3D avatars for the analysis of individual movement patterns.

CHEF (Characterisation of cognitive impairment in heart failure)

Characterization of cognitive profiles in subjects with heart failure and their correlation with biomarkers in blood and imaging features.

CSVD-Clearance (MRI-Based Imaging of Brain Clearance in Patients with Cerebral Small Vessel Disease)

Using a specialized native 7-Tesla MRI sequence, the study investigates whether cerebral clearance is altered in patients with cerebral microangiopathy compared to healthy controls.

DANCER (Establishment of a Recruitment Pool of Potential Study Participants, of Realtives and a Control Group for DZNE Studies)

One focus of these studies is the identification of early, specific changes, for example in the blood, so that the diagnosis of a neurodegenerative disease such as dementia or Parkinson's can be made at a very early stage. This enables a better understanding of the diseases and supports the development of new forms of therapy.

DANCER-FTD (Recruitment of Realtives and a Control Group for the DESCRIBE-FTD Study)

In order for us to assess study outcomes of patients with neurological frontotemporal dementia (FTD), comparative studies with relatives of patients with FTD as well as interested individuals without a diagnosis of neurodegenerative disease are needed.

DANCER-PSP (Recruitment of Realtives and a Control Group for the DESCRIBE-PSP Study)

Comparative studies with relatives of patients with PSP and interested individuals without a diagnosis of neurodegenerative disease are needed to assess study outcomes of patients with progressive supranuclear palsy (PSP).

DESCRIBE (DZNE - Clinical Register Study of neurodegenerative Disorders)

The aim of the DESCRIBE study is to use the examination results obtained in the course of normal patient care together with findings from diagnostics on biomaterials, including genetic analysis, for scientific purposes.

DESCRIBE-Cognition (DZNE - Klinische Registerstudie zur kognitiven Leistungsfähigkeit bei Alzheimer-Erkrankungen)

Alzheimer's disease is the most common cause of dementia. Although research has made progress in recent years, there are still many unanswered questions, particularly regarding the progression of the disease and early changes.

DESCRIBE-FTD/ALS (DZNE Clinical Registry Study on Frontotemporal Dementia (FTD) & on Amyotrophic lateral sclerosis (ALS))

The aims of this studies are to describe the course of FTD and ALS in detail, in their various characteristic clinical forms, to improve our understanding of the underlying pathology and to identify effective parameters for diagnosis and forecasting of the diseases' progression. This work is expected to illuminate the causes of the diseases, and to provide a basis for better therapies that can be applied at earlier stages of the diseases.

DESCRIBE-PD (DZNE Clinical Registry Study of Neurodegenerative Diseases on Patients with sporadic and familial Parkinson's syndromes (PD) and Idiopathic REM Sleep Behavior Disorder)

Longitudinal clinical observation is intended to identify subgroups of the disease with different clinical courses and determine their causes. In addition, the study aims to identify specific biomarkers to enable the earliest possible diagnosis and prognosis, as well as to differentiate the condition from other neurodegenerative diseases. Individuals with idiopathic REM sleep behavior disorder will also be included, as this may be a precursor to Parkinson’s disease.

DESCRIBE-PSP (DZNE - Clinical Registry Study on Progressive Supranuclear Paresis (PSP))

The aim of the DESCRIBE-PSP study is to document the early and atypical course of PSP in order to enable improved diagnostic criteria and therapy studies in the early course of the disease.

DESCRIBE-Treatment (DZNE - Clinical Registry Study on the documentation of innovative therapies)

The DZNE therefore aims to examine participants over time through regular assessments as part of this study. The study is open to people who are being treated with newly approved therapies or new therapies that become available in the future.

Donate your Gait - Untersuchung des Gangbildes bei gesunden Kontrollen

The Donate your Gait study is examining the gait of the general population with the aim of analyzing and quantifying normal gait.

DZNE-CAA (DZNE Cerebral Amyloid Angiopathy Study)

Cerebral amyloid angiopathy (CAA) is a disease of the vessels in the brain in which proteins, known as amyloid, are deposited in the walls of the vessels. There are initial indications of possible mechanisms and biomarkers that influence the course of the disease, but there are still many unanswered questions.

EfgaDem (A double-blinded, randomized, placebo-controlled, multi-center trial of Efgartigimod in autoimmune dementia)

In this clinical trial, it will be examined whether treating participants with progressive cognitive impairment or dementia with the drug Efgartigimod leads to stabilization or improvement of cognitive impairment, or to a slower rate of its progression.

ENABLE (Patient- and care-related benefits of amyloid PET imaging)

The aim of the ENABLE trial is to test whether amyloid PET screening has the potential to improve the care of dementia patients in the German health care system and thus contribute to the preservation or slowed loss of everyday functions.

ESMI (European Spinocerebellar Ataxia Type 3/Machado-Joseph Disease Initiative)

The aim of this study is to assemble a trial-ready cohort of sufficient size consisting of patients with spinocerebellar ataxia type 3 (SCA 3) and first-degree relatives, so-called at-risk individuals, for future drug trials.

HSP-Net (Networking Project on Hereditary Spastic Paraplegia)

Spastic spinal paralysis (HSP) is a rare, often hereditary, slowly progressive disease characterized by a spastic gait disorder. The HSP project involves the establishment and conduct of a multicenter study of the natural longitudinal course of hereditary spastic spinal paralysis.

MOTION-UE Stroke (Prospective validation of markerless motion capture for AI-based quantification of arm and hand motor function after stroke)

In this study, we investigate how modern digital methods can be used to more accurately assess impairments in arm and hand function following a stroke or a transient ischemic attack (TIA).

PROFA (Patient-reported, health economic and psychosocial outcomes in Friedreich Ataxia)

Investigation of the impact of Friedreich's ataxia on patient-related, health economic, and psychosocial outcomes using self-reported data collection via a patient-centered e-health app.

PROMINENT (Improving the management of Alzheimer’s disease)

PROMINENT is a collaborative pan-European public-private partnership funded through the Innovative Health Initiative (IHI). It will create a digital platform for precision medicine to improve the diagnosis and treatment of neurodegenerative disease and co-morbidities to assist clinicians with individualised decision support in the evaluation of patients with suspected cognitive impairment.

Refer-MCI (Enriching referrals of patients to memory clinics for mild cognitive impairment (MCI))

The use of digital technologies is intended to optimize the referral practice of patients with MCI to memory clinics. The study will examine how digital self-testing tools can improve referral practice, what role biomarkers play in identifying MCI due to Alzheimer's disease, and how these digital tools compare to established tests.

Reτain (A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease)

The purpose of this study is to assess the effect of JNJ-64042056 on cognitive decline, as measured by Preclinical Alzheimer's disease Cognitive Composite 5 (PACC-5) compared with placebo.

SCA Registry (Registry for Spinocerebellar Ataxies (SCA))

The goals of the SCA Registry are to characterize the natural history of the disease, identify prognostic factors, and develop novel imaging and biochemical biomarkers. By including at-risk individuals, we place a special focus on studying the preclinical disease phase.

SPORTAX-NHS (Observational Study on Adult Onset Sporadic Ataxias)

The SPORTAX study aims to precisely characterize the two forms of the disease and to compare the courses of the disease. In addition, factors are to be identified that allow a more precise assignment of the disease at an early stage and that can influence the development of the disease.